Piper Jaffray analyst David Amsellem polled 25 nephrologists who manage a significant number of hemodialysis patients to gauge perceptions of the intravenous form of Cara Therapeutics' Korsuva in pruritus associated with chronic kidney disease. There is good familiarity with the body of data in the dialysis setting, most respondents perceive an unmet medical need, and most respondents have favorable impressions of Cara's data, Amsellem tells investors in a research note. The analyst says the survey reinforced our view that IV Korsuva will emerge as a valued anti-pruritic in hemodialysis patients. He views the U.S. sales opportunity "well north" of $400M-$500M and reiterates an Overweight rating on Cara Therapeutics with a $35 price target.